Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
14.57
-0.53 (-3.51%)
At close: Aug 25, 2025, 4:00 PM
14.57
0.00 (0.00%)
After-hours: Aug 25, 2025, 4:37 PM EDT
Zymeworks Employees
As of December 31, 2024, Zymeworks had 286 total employees, including 280 full-time and 6 part-time employees. The number of employees increased by 8 or 2.88% compared to the previous year.
Employees
286
Change (1Y)
8
Growth (1Y)
2.88%
Revenue / Employee
$429,605
Profits / Employee
-$257,605
Market Cap
1.10B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 286 | 8 | 2.88% |
Dec 31, 2023 | 278 | -16 | -5.44% |
Dec 31, 2022 | 294 | -164 | -35.81% |
Dec 31, 2021 | 458 | 103 | 29.01% |
Dec 31, 2020 | 355 | 99 | 38.67% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ZYME News
- 6 days ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 14 days ago - Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry - GlobeNewsWire
- 17 days ago - Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate - GlobeNewsWire
- 5 weeks ago - Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - GlobeNewsWire
- 2 months ago - Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade) - Seeking Alpha
- 3 months ago - Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewsWire